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Abstract
Background—Type D (distressed) personality and medication nonadherence have been 
associated with poor health outcomes. Type D personality is associated with poor medication 
adherence in patients with coronary artery disease. However, the relationship between type D 
personality and medication adherence in patients with heart failure (HF) remains unknown.
Purpose—Therefore, the goal of this study was to examine the association between type D 
personality and medication adherence in patients with HF.
Method—This was a sub-analysis of baseline data from a randomized controlled trial with 84 
patients with HF in the USA. Demographic, clinical, and psychological data were collected at 
baseline by interview, questionnaires, and medical record review. Type D personality was 
assessed using the Type D Personality Scale (DS14). Medication adherence was measured using 
both objective (Medication Event Monitoring System, MEMS) and self-reported (Morisky 
Medication Adherence Scale, MMAS-4) measures. Patients started medication adherence 
monitoring with the MEMS bottle at baseline and is used continuously for a month. Multiple 
regressions were used to explore the relationships between type D personality and medication 
adherence while adjusting for demographic, clinical, and psychological factors.
Results—Patients with type D personality were more likely to have poor medication adherence. 
Type D personality was associated with medication adherence before and after adjusting for 
covariates when it was analyzed as a categorical variable. However, type D personality was not 
associated with medication adherence when analyzed as a dimensional construct. Negative 
affectivity, a component of type D personality, was associated with medication adherence.
Conclusion—As a dimensional construct, type D personality may not reflect the components of 
the personality associated with poor outcomes. Negative affectivity was associated with 
medication adherence in patients with HF. Interventions aiming to improving/enhancing 
medication adherence need to take into account patients with the negative affectivity component 
of type D personality who are at higher risk for poor medication adherence, which may lead to 
adverse health outcomes.
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Introduction
Many investigators have investigated the association of type D personality with clinical 
outcomes. Type D personality is a distressed personality that includes two stable personality 
traits: negative affectivity (NA) and social inhibition (SI) [1]. Individuals with a type D 
personality tend to experience increased negative emotions and tend not to share their 
emotions with others [1]. Previous research suggests that type D personality may be 
associated with poor health, including expressions of poor quality of life [2-4], greater 
number of cardiac symptoms and feelings of disability [5], major psychosocial stressors [6], 
impaired physical and mental health [3], morbidity [6-9], and even mortality [9-13] in the 
general population [14], and among patients with non-cardiovascular disease [15] and 
cardiovascular disease patients [7, 9, 11-13, 16, 17]. Some investigators, however, have 
failed to demonstrate a relationship between type D personality and mortality [18-21]. The 
null findings on mortality may be due to the low prevalence of type D personality [18, 19], 
high level of social support in the population [21], short follow-up periods [18, 19], 
differences in use of the construct as a categorical or dimensional variable [18], and cultural 
differences [20] in these studies.
Mols and Denollet [14] reviewed studies published from 2002 to 2009 concerning type D 
personality among the general population. The investigators concluded that type D 
personality was associated with symptoms of depression and anxiety, more somatic 
complaints and reports of poorer health, higher rates of absences, and more work-related 
stress [14]. In another recent review [15] of studies published from 2007 to 2009 on the 
implications of type D personality among non-cardiovascular patient populations, the 
investigators found that type D personality was associated with an increased severity of 
reported health complaints, heightened perception of negative emotions (depression and 
anxiety), poor adherence to treatment, and significantly reduced effort to perform during 
diagnostic testing, and had an adverse effect on health-related behaviors.
Type D personality may be a psychosocial risk factor for morbidity and mortality in patients 
with cardiovascular disease [16]. For example, Denollet and colleagues [8] followed 319 
patients with coronary heart disease (CHD) for 5 years and found that type D personality 
measured at baseline was an independent predictor of future cardiac events. Patients with 
type D personality were 8.9 times more likely to experience a cardiac event compared to 
those without a type D personality [8]. In a prospective study, Martens and colleagues 
followed 473 patients hospitalized for acute myocardial infarction (MI) for 1.8 years and 
found that patients with type D personality had a twofold increased risk of total death/
recurrent MI after adjusting for disease severity and depression and had a more than 
threefold increased risk of late death/recurrent MI [9]. In another prospective study, type D 
personality was a significant predictor of both cardiac and noncardiac death in 303 patients 
with CHD [17]. In the heart failure (HF) literature, patients with HF and type D personality 
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were more likely to experience worse health-related quality of life [2-4], report more 
depressive symptoms [2], and have a higher incidence of cardiac mortality [10] compared 
with non-type D HF patients.
There is evidence for a number of potential biological mechanisms that could explain the 
relationship between type D personality and poor health outcomes in HF, such as higher 
level of proinflammatory cytokines (e.g., tumor necrosis factor-α) [22, 23], increased 
oxidative stress burden, and decreased antioxidant level [24]. There is also evidence for 
behavioral mechanisms linking type D personality with adverse outcomes, including self-
management behaviors in patients with HF. For example, HF patients with type D 
personality were more likely to have inadequate consultation seeking behavior even though 
they experienced more HF symptoms and appraised these symptoms as worrisome [25]. 
Failure to consult for HF symptoms increased risk of reporting impaired health status [26]. 
Moreover, type D personality was associated with nonadherence to respiratory treatment for 
patients with obstructive sleep apnea syndrome [27, 28].
Medication adherence is an essential self-management behavior in patients with chronic 
conditions [29]. To our knowledge, there are two recent studies in which the relationship 
between type D personality and medication adherence was examined [30, 31]. One study 
showed that type D personality as a dimensional construct was associated with poor 
medication adherence in patients with MI [31]. The other study demonstrated the same 
results in patients with acute coronary syndrome (ACS) when type D personality was 
measured as a categorical variable [30]. However, the relationship between type D 
personality and medication adherence in patients with HF remains unknown. HF is a chronic 
condition with high prevalence and incidence, and poor outcomes that requires patients to 
consistently take their prescribed medications to prevent emergency department visits, 
hospital admissions, or death [32-37]. Pharmacological treatment is vital for patients with 
HF to control symptoms and reduce hospitalizations and death [38, 39]. Therefore, 
medication adherence is essential to prevent morbidity and mortality in HF [40-42]. The 
purpose of this study was to determine the association between type D personality and 
medication adherence in patients with HF.
A recent taxometric analysis of the measure of type D personality has shown that type D 
personality may be better considered as a dimensional construct than a categorical construct 
[43]. There have been substantial concerns about the use of potentially artificial cut points to 
construct typology which may result in the likelihood of spurious results [44, 45]. There 
were two studies in which the impact of the dimensional construct of type D personality on 
medication adherence was examined with inconsistent findings [30, 31]. One study showed 
that type D personality predicted medication adherence [31]. In the other study, the 
investigator did not find a relationship between type D personality and medication 
adherence when type D personality was analyzed dimensionally (the interaction of NA and 
SI) [30]. Therefore, we aimed to determine whether type D personality was associated with 
medication adherence when analyzed as a dimensional construct in patients with HF.
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This was a sub-analysis of baseline data of a randomized control trial in patients with HF. 
Demographic, clinical, and psychological data were collected by interview, questionnaires, 
and medical record review.
Sample and Setting
Detailed eligibility criteria and recruitment methods have been published previously [46]. 
Briefly, we recruited patients from the outpatient cardiology clinic and inpatient hospital in 
the Southern region of the USA. Patients with a confirmed diagnosis of chronic HF who 
were on stable doses of HF medications were enrolled in the study. Patients with obvious 
cognitive impairment (i.e., could not give informed consent or participate in an interview) 
and any coexisting terminal illness (e.g., end stage renal disease) were excluded.
Measurement of Variables
Type D Personality—Type D personality, negative affectivity, and social inhibition were 
assessed using the Type D Scale (DS-14) [47] at baseline, a 14-item questionnaire that 
included asking people if they would describe themselves with phrases such as, “I am a 
closed person” and “I often feel unhappy.” The items were answered on a five-point Likert 
scale from 0 (false) to 4 (true). Seven items refer to NA, and seven items refer to SI. The 
total scores for NA and SI subscales can range from 0 to 28 to assess personality traits. 
People who scored 10 points or more on both the NA and SI subscales were classified as 
type D personality. The DS-14 is a reliable and valid instrument that has been used to 
measure type D personality, NA, and SI in patients with hypertension [47], MI [31], and HF 
[3, 10, 24]. In this study, Cronbach's alpha was 0.86 and 0.82 for the NA and SI subscales, 
respectively.
Medication Adherence—As there is no “gold standard” measure for medication 
adherence, we used both self-reported (Morisky Medication Adherence Scale, MMAS-4) 
and objective (Medication Event Monitoring System, MEMS) measures to increase the 
accuracy of assessment. First, medication adherence was assessed using the MMAS-4 [48]. 
Patients were asked to answer four items [yes (score=1), no (score=0)], assessing how often 
over the last month medication was not taken for four reasons: forgetting to take it, being 
careless about taking it, not taking it because they felt better, and not taking it because they 
felt worse. The scores of the four items are summed for a total score that can range from 0 to 
4; higher scores indicate poorer medication adherence. The MMAS-4 has demonstrated 
acceptable internal consistency (Cronbach's α =0.61) and has been used to measure 
medication adherence in patients with hypertension [48] and HF [49].
Medication adherence was also measured objectively for 1 month (starting at baseline) using 
a microelectronic medication monitoring device (MEMS, AARDEX®-USA, Union City, 
CA) in the cap of a medication vial. Real-time data were recorded when the cap was 
removed. MEMS data were collected for one HF medication. Our previous studies 
demonstrate that monitoring of one medication is sufficient to capture overall medication 
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adherence [50, 51]. The medication chosen for monitoring using the MEMS was selected in 
the following order: beta-adrenergic antagonist agent, angiotensin-converting-enzyme 
inhibitor, angiotensin receptor blocker, aldosterone antagonist, digoxin, or a diuretic. A 
MEMS diary was given to patients to record MEMS cap openings that were not related to 
taking medication such as refilling the bottle without taking medication. All cap openings 
unrelated to taking medications were deleted from the analysis. Medication adherence from 
the MEMS was defined as the dose–count, which is the percentage of prescribed doses taken 
during the monitoring period [42].
Other Variables of Interest—Age [52], gender [52, 53], ethnicity [26, 54], education 
level [33, 55, 56], left ventricular ejection fraction (a measure of ventricular function) [26, 
57], comorbidity [58, 59], and perceived social support [26, 60, 61], which might influence 
medication adherence, were collected as covariates from the medical records or patient 
interview to adjust in the multiple regression. We also collected patients' marital status, body 
weight and height to calculate body mass index (BMI), New York Heart Association 
functional classification (NYHA), angiotensin-converting enzyme inhibitor use, and beta-
antagonist use from patient interview and medication records to characterize patients by 
groups. Perceived social support was assessed using the Multidimensional Perceived Social 
Support Scale (MPSSS). The MPSSS is a reliable and valid instrument [62, 63]. Internal 
consistency of the MPSSS for this study was demonstrated by a Cronbach's alpha of 0.85. 
BMI was calculated as weight (in kilogram)/height (in square meter).
Procedure
The study was approved by the appropriate Institutional Review Boards. Patient eligibility 
was confirmed by a trained nurse who then explained study requirements to the patients and 
invited them to participate. At baseline, after obtaining an informed consent, the patient's 
demographic and clinical characteristics were collected by interview and medical record 
review, and patients completed the questionnaires (included DS-14 and MMAS-4). Detailed 
written and verbal instructions on use of the MEMS bottle were then given to patients. 
Patients were instructed to take the specified medicine from the MEMS bottle continually 
for the monitoring period and to close the cap after each use. Patients who used a pill box 
were asked to keep the MEMS bottle next to their pill box and take that medicine from the 
MEMS bottle. An appointment was made 1 month later. At this visit, patients' MEMS data 
were downloaded to a personal computer and transferred into a database for analysis.
Data Analysis
All data analyses were performed using SPSS (Chicago, IL), version 18.0; an alpha level of 
<0.05 was used. Data analysis began with a descriptive examination of all variables, 
including frequency distributions, means, standard deviations, medians, and interquartile 
ranges, as appropriate to the level of measurement of the variables. We compared 
differences in demographic and clinical factors between groups using chi-square and t tests. 
Medication adherence was analyzed as a continuous variable. Nonparametric Spearman's 
rho was used to examine the correlation between medication adherence measured by the 
MMAS-4 and the MEMS. Multiple regression analyses were used to explore the relationship 
between type D personality and medication adherence while adjusting for demographic (age, 
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gender, and ethnicity), clinical (LVEF and comorbidities), and psychological (perceived 
social support) factors.
As recommended by Ferguson and colleagues [43], to avoid using an artificial cut point and 
to use the full range of the data generated by the measures of type D personality, NA, SI, 
and type D personality were analyzed as continuous variables. In the multiple regression 
analysis, we entered continuous NA and SI measures and their interaction term (NA by SI) 
to determine the effect of type D personality when it is treated as a dimensional construct 
[30, 31].
We also conducted sensitivity analyses by reducing the number of covariates for which we 
adjusted (i.e., only included age, education level, comorbidities, and perceived social 
support) in the multiple regression models.
Results
Patient Characteristics
A total of 84 patients with HF were included in this study. The mean age of patients was 
60±13 years. About half of the patients were female. Half of patients were classified as 
NYHA class III or IV. Most patients had three other chronic comorbid conditions in addition 
to their HF. Full sample characteristics are presented in Table 1.
Type D Personality, Negative Affectivity, and Social Inhibition
The mean (SD) total score of the DS-14 was 16.2 (10.5). About one quarter (23.8 %) of the 
patients were identified as type D personality according to the cut point of 10 on both NA 
and SI subscales. Patients with type D personality were younger, had less education, and had 
more comorbidities compared to those without type D personality (Table 1).
The mean (SD) NA score was 7.7 (6.2), and the mean (SD) SI score was 8.4 (6.1). One third 
of the patients had the NA personality trait and about half (42.9 %) of the patients had the SI 
personality trait when the cut point 10 was used. Patients with NA personality were younger 
and had more comorbidities compared to those without this personality trait. No 
demographic and clinical characteristics differed between patients with and without the SI 
personality trait.
Medication Adherence and Type D Personality
More than half (52 %) of the patients in this study reported that they did not miss taking any 
of their medications. The mean medication adherence measure by the MEMS was 93.5 %. 
The correlation between medication adherence measured by the MMAS-4 and the MEMS 
was significant but weak (rho= 0.283, p =0.01). There was a gap between the results of self-
reported adherence and adherence measuring using the MEMS: about half of participants 
(47 %) who self-reported that they did not miss taking any of their medications only took 
less than 80 % of their medications as assessed using the MEMS (p =0.009).
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MMAS-4 and Type D Personality
Type D personality when analyzed as a categorical variable was associated with medication 
adherence regardless of whether medication adherence was measured by the MMAS-4 or 
the MEMS. When medication adherence was assessed using the MMAS-4, patients with 
type D personality had poorer medication adherence compared with those without type D 
personality (1.05 vs. 0.56, p = 0.027). In multiple regression (Table 2), type D personality 
was associated with medication adherence before and after adjusting for demographic (age, 
gender, ethnicity, and education level), clinical (LVEF and comorbidities), and 
psychological (perceived social support) factors (p =0.027 and 0.042, respectively). The 
model as a whole explained 19 % of the variance in medication adherence, with type D 
personality by itself explaining 5 % of variance.
In addition to type D personality, we also examined the effect of its components NA and SI 
on medication adherence. Only patients with NA had poorer medication adherence 
compared with those without NA (1.00 vs. 0.52, p =0.015). In the regression models, NA 
was associated with medication adherence before and after adjusting for demographic, 
clinical, and psychological factors (p = 0.044 and 0.016, respectively). SI personality trait 
was not associated with medication adherence.
When type D personality, NA, and SI were analyzed as continuous variables, we had similar 
results. Type D personality was associated with medication adherence before and after 
adjusting for the same covariates (p =0.011 and 0.033, respectively) when measured by the 
MMAS-4. Likewise, when NA and SI were entered as continuous variables in the model, 
only NA was associated with medication adherence (p =0.026). However, when NA, SI, and 
their interaction term were entered in the multiple regression, none of them were associated 
with medication adherence (Table 3).
MEMS and Type D Personality
When medication adherence was assessed using the MEMS, patients with type D personality 
had poorer medication adherence compared with those without type D personality (88.9 vs. 
95.0, p =0.03). In multiple regression (Table 4), type D personality was associated with 
medication adherence when measured by the MEMS before and after adjusting for same 
demographic, clinical, and psychological factors (p =0.03 and 0.043, respectively). The 
model explained 13 % of the variance in medication adherence, with type D personality by 
itself explaining 5 % of variance.
When the components of type D personality, NA, and SI were used in the model, only 
patients with NA had poorer medication adherence compared with those without NA (95 vs. 
90, p =0.042). In the regression models, NA personality trait (p =0.042), but not SI (p 
=0.098) was associated with medication adherence.
When type D personality, NA, and SI were analyzed as continuous variables, type D 
personality was associated with medication adherence before (p =0.049), but not after (p = 
0.121) adjusting for the same covariates. When NA and SI were entered as continuous 
variables in the model, only NA was associated with medication adherence (p = 0.038). 
When type D personality was analyzed as a dimensional construct, the associations between 
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NA, SI, their interaction term, and medication adherence revealed no significant results 
(Table 5).
Sensitivity Analysis
When we reduced the number of covariates to include only age, education level, 
comorbidities, and perceived social support in the multiple regression models, we found 
similar results. When type D personality was analyzed as a categorical variable, type D was 
associated with medication adherence no matter medication adherence was assessed using 
the MMAS-4 (p =0.032) or the MEMS (p =0.040) after adjusting for covariates. When type 
D personality was analyzed as a continuous variable, type D was associated with medication 
adherence when it was assessed using the MMAS-4 (p = 0.034), but not using the MEMS (p 
=0.117) after adjusting for covariates. Likewise, when type D personality was analyzed as a 
dimensional construct, NA, SI, and their interaction term were not associated with 
medication adherence no matter medication adherence was assessed using the MMAS-4 or 
the MEMS after adjusting for covariates.
Discussion
In this study, we explored the association between type D personality and medication 
adherence in patients with HF. To our knowledge, this is the first study to examine the 
relationship between type D personality and medication adherence in this patient population. 
However, we had two conflicting findings. We found that type D personality was associated 
with medication adherence when type D personality was analyzed as a categorical variable 
using both objective and self-reported measures of adherence before and after adjusting for 
demographic, clinical, and psychosocial variables, but when analyzed as a dimensional 
construct, type D personality was not associated with medication adherence.
Our findings that type D personality was associated with medication adherence when type D 
personality was analyzed as a categorical variable are consistent with previous research on 
the adverse effects of type D personality on self-management behaviors. It is worthy to note 
that most research studied the relationship between type D personality and self-management 
behaviors analyzed type D personality as a categorical variable [25, 27, 28]. Schiffer and 
colleagues [25] examined whether type D personality predicted poor self-management and 
failure to consult for cardiac symptoms in 178 outpatients with HF and found that HF 
patients with type D personality experienced more HF symptoms (i.e., shortness of breath, 
fatigue, and sleep problems, odd ratio (OR)=6.4). However, they were less likely to report 
these symptoms to their health care providers and had an increased risk for inadequate 
consultation behavior (OR = 2.7). In another study, HF patients with type D personality who 
displayed inadequate consultation behavior were at a sixfold increased risk of reporting 
impaired health status, compared to those without type D personality who displayed 
adequate consultation behavior [64]. Moreover, Brostrom and associates examined the 
relationship between type D personality and continuous positive airway pressure (CPAP) 
adherence in 247 outpatients with obstructive sleep apnea syndrome and found that CPAP 
adherence was significantly lower for patients with type D personality [27]. Likewise, 
Dieltjens and colleagues [28] found that the odds ratio for nonadherence to mandibular 
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advancement device, an alternative treatment for patients with sleep apnea, was 6.03 for 
type D personality adjusted for covariates. These findings suggest that patients with type D 
personality had more difficulties following self-management behaviors.
Adherence to prescribed medication is critical for patients with HF to have better health 
outcomes [40-42]. Previous studies have shown that some biological factors (e.g., cytokines 
[22, 23] and antioxidant level [24]) may explain the relationship between type D personality 
and cardiac events. However, the underlying linkages for the type D personality and poor 
outcomes are largely unknown. Our findings of this study when type D personality was 
analyzed as a categorical variable suggest another possible behavioral link between type D 
personality and adverse health outcomes—that is, poor adherence to prescribed medication.
However, type D personality was not associated with medication adherence when analyzed 
as a dimensional construct. Our study needs to be considered in light of the findings from 
similar studies. To date, there have been two investigations examining the relationship 
between the dimensional construct of type D personality and medication adherence [30, 31]. 
Our findings were consistent with one study which showed that dimensional type D 
personality was not independently associated with medication adherence in patients with 
ACS [30]. However, the other study did show that type D personality as measured as a 
dimensional construct predicted medication adherence in patients with MI [31]. We do not 
know why type D personality was associated with medication adherence when type D 
personality when analyzed as a continuous variable, categorically, but not dimensionally 
(continuous NA and SI measures and their interaction term). Some researchers had 
considerable concerns regarding approaches to conceptualization of type D personality, 
namely a dimensional or categorical construct [43, 65]. There also have been a number of 
null findings published recently between type D personality and outcomes or self-care 
behaviors [18-21, 30, 65]. Our findings—in conjunction with prior researchers'—suggest 
there may not be a robust relationship between type D personality and medication 
adherence. Additional research is needed to prospectively examine and verify the 
relationship between the dimensional construct of type D personality on medication 
adherence in patients with HF.
In line with the earlier study [30], our data showed the NA personality trait analyzed as 
either dichotomized or continuous variable was independently associated with medication 
adherence using both objective and self-reported measures of medication adherence, 
suggesting the primacy of NA over the type D personality in association with medication 
adherence.
It is interesting to note that the correlation between objective adherence and self-reported 
measure was significant but weak: high mean objective adherence (93.5 %); but only 52 % 
of the participants self-reported that they did not miss taking any of their medications. We 
previously reported that there was a gap between the results of self-reported adherence and 
adherence measuring using the MEMS [42]. In the current study, we found that about half of 
participants that self-reported that they did not miss taking any of their medications only 
took less than 80 % of their medications as assessed using the MEMS. Though self-reported 
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medication adherence is feasible and may provide a gross indicator of adherence [48], it 
should be interpreted with caution in clinical settings and future studies.
In a recent review, the prevalence of type D personality ranged from 27 to 31 % in patients 
with cardiovascular disease [15]. The prevalence of type D personality ranged from 18.2 to 
32 % in patients with HF [3, 4, 24, 64]. In our study, the prevalence of type D personality in 
patients with HF was 23.8 %. Therefore, our finding is consistent with the current HF 
literature.
The results of this study are limited by the small sample size and, therefore, we only can 
adjust some potential confounders that might have an impact on medication adherence in the 
multiple regression models. In our sensitivity analyses, we reduced the covariates to four 
variables in the multiple regression models and had similar results. However, future studies 
of this phenomenon should include a larger sample so that the complex dynamics 
surrounding type D personality and medication adherence can be better illuminated. The 
relatively small effect size also may produce unstable results especially in multiple 
regression models that need to be verified in a larger sample. Thus, our findings should be 
considered exploratory and the need for replication emphasized. Also, this was a sub-
analysis of baseline data of an intervention study in patients with HF. To compare 
participants' objective medication adherence before and after intervention and also to sustain 
the participants in the study in this fragile patient population, medication adherence before 
the intervention was measured by the MEMS for 1 month. The 1-month monitoring period 
might be a little short to reflect participants' medication adherence. The strength of this 
study is that it is the first study to examine the relationship between type D personality and 
medication adherence in patients with HF by using both self-reported and an objective 
measures to assess medication adherence.
Conclusion
Type D personality was associated with medication adherence when it was analyzed as a 
categorical variable, but not associated with medication adherence when analyzed as a 
dimensional construct. Negative affectivity was associated with medication adherence in 
patients with HF. Thus, screening for type D personality, especially for the NA personality 
trait in patients with HF may help to identify those who are at higher risk of poor medication 
adherence. Interventions aiming to improving/enhancing medication adherence need to take 
into account patients with negative affectivity personality who are at higher risk for 
medication nonadherence, which may lead to adverse health outcomes.
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Table 1
Sample characteristics
Characteristics Total sample (N =84) Type D (n =20) Non-type D (n =64) p value
Age, years (mean ± SD) 60±13 56±13 61±13 0.037
Female 37 (44 %) 10 (50 %) 27 (42 %) 0.610
Ethnicity
 Caucasian 65 (77 %) 12 (60 %) 53 (83 %) 0.062
Education, years (mean ± SD) 14.0±3.6 12.5±2.4 14.5±3.8 0.008
Marital status 0.090
 Married/cohabitate 49 (58 %) 9 (45 %) 40 (62.5 %)
 Single 13 (16 %) 7 (35 %) 6 (9.4 %)
 Divorced 17 (20 %) 3 (15 %) 14 (21.9)
 Widowed 5 (6 %) 1 (5 %) 4 (6.3 %)
BMI (mean ± SD) 32.9±8.8 34±7.8 32.5±9.2 0.508
LVEF (mean ± SD), % 38.0±14.2 38.6±16.5 37.8±13.5 0.821
NYHA functional class
 III/IV 42 (50 %) 12 (60 %) 30 (47 %) 0.443
Charlson comorbidity index (mean ± SD) 3.1±1.9 4±2.3 2.8±1.7 0.038
Perceived social support 67.9±21.0 70.2±23.2 67.2±20.5 0.588
Taking ACEI 58 (70 %) 16 (80 %) 42 (67 %) 0.402
Taking BB 80 (95 %) 20 (100) 60 (94 %) 0.568
Medication adherence (mean ± SD) as measured by the 
MMSA-4
0.68±0.87 1.05±1.05 0.56±0.77 0.027
Medication adherence (mean ± SD) as measured by the MEMS 93.5±10.8 88.9±17.6 95.0±7.4 0.03
BMI body mass index, LVEF left ventricular ejection fraction, NYHA New York Heart Association, ACEI angiotensin-converting-enzyme inhibitor, 
BB beta-blocker, MMAS-4 Morisky Medication Adherence Scale, MEMS Medication Event Monitoring System
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Table 2
The association of type D personality and medication adherence (N =84)
Variables Beta 95 % CI p value Total R2
Unadjusted model*
 Type D personality −0.241 −0.919 to −0.056 0.027
Adjusted model**
 Step 1 10 %
  Age −0.169 −0.026 to 0.003 0.125
  Gender 0.228 0.008 to 0.788 0.046
  Ethnicity 0.046 −0.364 to 0.552 0.684
  Education −0.042 −0.063 to 0.043 0.707
 Step 2 14 %
  Left ventricular ejection fraction 0.009 −0.013 to 0.014 0.939
  Comorbidity −0.086 −0.143 to 0.065 0.459
  Perceived social support −0.196 −0.017 to 0.001 0.077
 Step 3 19 %
  Type D personality −0.239 −0.949 to −0.017 0.042
As measured by the Morisky Medication Adherence Scale-4
*
F =5.059, p =0.027;
**
F =2.179, p =0.039 (adjusting for age, gender, ethnicity, education, left ventricular ejection fraction, comorbidity, and perceived social support)
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Table 3
Negative affectivity, social inhibition, and medication adherence (N =84)
Variables Beta 95 % CI p value
Step 1
 Age −0.169 −0.026 to 0.003 0.125
 Gender 0.228 0.008 to 0.788 0.046
 Ethnicity 0.046 −0.364 to 0.552 0.684
 Education −0.042 −0.063 to 0.043 0.707
Step 2
 Left ventricular ejection fraction 0.009 −0.013 to 0.014 0.939
 Comorbidity −0.086 −0.143 to 0.065 0.459
 Perceived social support −0.196 −0.017 to 0.001 0.077
Step 3
 Negative affectivity 0.289 0.005 to 0.076 0.026
 Social inhibition 0.008 −0.033 to 0.036 0.949
Step 4
 Negative affectivity 0.271 −0.020 to 0.096 0.196
 Social inhibition −0.008 −0.053 to 0.051 0.967
 Negative affectivity × social inhibition 0.032 −0.004 to 0.005 0.911
As measured by the Morisky Medication Adherence Scale-4
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Table 4
The association of type D personality and medication adherence (N =84) Variables
Variables Beta 95 % CI p value Total R2
Unadjusted model*
 Type D personality 0.239 0.598 to 11.638 0.03
Adjusted model
 Step 1 6 %
  Age 0.221 −0.003 to 0.394 0.054
  Gender −0.010 −5.368 to 4.911 0.930
  Ethnicity 0.008 −5.766 to 6.180 0.945
  Education 0.077 −0.465 to 0.932 0.507
 Step 2 8 %
  Left ventricular ejection fraction −0.076 −0.239 to 0.123 0.524
  Comorbidity 0.088 −0.908 to 1.931 0.475
  Perceived social support 0.114 −0.059 to 0.175 0.326
 Step 3 13 %
  Type D personality 0.247 0.206 to 12.397 0.043
As measured by the Medication Event Monitoring System
** F =1.329, p =0.243 (adjusting for age, gender, ethnicity, education, left ventricular ejection fraction, comorbidity, and perceived social support)
*
F =4.865, p =0.03;
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Table 5
Negative affectivity, social inhibition, and medication adherence (N =84)
Variables Beta 95 % CI p value
Step 1
 Negative affectivity −0.254 −0.857 to −0.026 0.038
 Social inhibition −0.003 −0.429 to 0.418 0.980
Step 2
 Negative affectivity −0.274 −0.171 to 0.218 0.176
 Social inhibition −0.022 −0.708 to 0.632 0.910
 Negative affectivity × social inhibition 0.035 −0.052 to 0.059 0.900
As measured by the Medication Event Monitoring System
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